Meeting
2023 ASCO Annual Meeting
89Zr-DFO-girentuximab for PET/CT imaging of clear cell renal cell carcinoma: Results from phase 3 ZIRCON study.
Authors
Brian M. Shuch
Institute of Urologic Oncology, David Geffen School of Medicine at UCLA, Los Angeles, CA
Brian M. Shuch , Allan J. Pantuck , Jean-Christophe Bernhard , Michael Morris , Viraj A. Master , Andrew Mark Scott , Charles Van Praet , Clément Bailly , Bulent Onal , Tamer Aksoy , Robin Merkx , David M. Schuster , Sze Ting Lee , Neeta Pandit-Taskar , Alice C. Fan , Libuse Tauchmanova , Karl Schmidt , Kavita Vadali , Colin Hayward , Peter Mulders
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary Cancer—Kidney and Bladder
Track
Genitourinary Cancer—Kidney and Bladder
Sub Track
Kidney Cancer
Clinical Trial Registration Number
NCT03849118
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 4554)
DOI
10.1200/JCO.2023.41.16_suppl.4554
Abstract #
4554
Poster Bd #
46
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
Pre-surgical 68Ga-PSMA-11 PET for biochemical recurrence risk assessment: A surrogate of pelvic lymph node dissection? Follow-up analysis of a multicenter prospective phase 3 imaging trial.
First Author: Loic Djaileb
Poster
2024 ASCO Genitourinary Cancers Symposium
Impact of standard-of-truth method on evaluation of a diagnostic PET radiopharmaceutical: Learnings from the phase 3 SPOTLIGHT study.
First Author: Benjamin H. Lowentritt
Poster
2023 ASCO Annual Meeting
Pre-surgical 68Ga-PSMA-11 PET for biochemical recurrence risk assessment: A surrogate of pelvic lymph node dissection? Follow-up analysis of a multicenter prospective phase 3 imaging trial.
First Author: Loic Djaileb
Poster
2023 ASCO Annual Meeting
First-in-human clinical trial design of a first-in-class theranostic approach with a peptide-based radioligand targeting CA IX-expressing tumors.
First Author: Darren R. Feldman